Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?

Eli Lilly and Company (LLY) has seen unparalleled success with tirzepatide, a dual GIP and GLP-1 receptor agonist, which is marketed as Mounjaro for type II diabetes and Zepbound for obesity.Mounjaro was launched in mid-2022, while Zepbound was launched in November 2023. Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly, with demand for weight loss drugs rising rapidly. Tirzepatide is also being developed for other indications, including obstructive sleep a ...